Pharmacokinetic evaluation of almotriptan for the treatment of migraines

Bibliography

• Vos T, Flaxman AD, Naghavi M, Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012;380(9859):2163-96
   PubMed Web of Science ®Google Scholar
• Steiner TJ, Stovner LJ, Birbeck GL. Migraine: the seventh disabler. J Headache Pain 2013;14:1
   PubMed Web of Science ®Google Scholar
• Martelletti P, Birbeck GL, Katsarava Z, The Global Burden of Disease survey 2010, lifting the burden and thinking outside-the-box on headache disorders. J Headache Pain 2013;14:13
   PubMed Web of Science ®Google Scholar
• Negro A, Rocchietti-March M, Fiorillo M, Chronic migraine: current concepts and ongoing treatments. Eur Rev Med Pharmacol Sci 2011;15:1401-20
   PubMed Web of Science ®Google Scholar
• Negro A, Martelletti P. Chronic migraine plus medication overuse headache: two entities or not? J Headache Pain 2011;12:593-601
   PubMed Web of Science ®Google Scholar
• Tepper SJ, Rapoport AM, Sheftell FD. Mechanisms of action of the 5-HT1B/1D receptor agonists. Arch Neurol 2002;59:1084-8
   PubMed Web of Science ®Google Scholar
• Link AS, Kuris A, Edvinsson L. Treatment of migraine attacks based on the interaction with the trigemino-cerebrovascular system. J Headache Pain 2008;9:5-12
   PubMed Web of Science ®Google Scholar
• Hamel E. Serotonin and migraine: biology and clinical implications. Cephalalgia 2007;27:1295-300
   Web of Science ®Google Scholar
• Tepper J, Stillman J. What is the best drug-delivery approach for the acute treatment of migraine? Expert Rev Neurother 2012;12:253-5
   PubMed Web of Science ®Google Scholar
• Calatayud-Pascual MA, Balaguer-Fernández C, Serna-Jiménez CE, Effect of iontophoresis on in vitro transdermal absorption of almotriptan. Int J Pharm 2011;416(1):189-94
   PubMed Web of Science ®Google Scholar
• Gentile G, Borro M, Lala N, Genetic polymorphisms related to efficacy and overuse of triptans in chronic migraine. J Headache Pain 2010;11:431-5
   PubMed Web of Science ®Google Scholar
• Gentile G, Missori S, Borro M, Frequencies of genetic polymorphisms related to triptans metabolism in chronic migraine. J Headache Pain 2010;11:151-6
   PubMed Web of Science ®Google Scholar
• Bou J, Domenech T, Puig J, Pharmacological characterizacion of almotriptan: an indolic 5-HT receptor agonist for the treatment of migraine. Eur J Pharmacol 2000;410:33-41
   PubMed Web of Science ®Google Scholar
• Sandrini G, Perrotta A, Buscone S, Almotriptan in the treatment of migraine. Neuropsychiatr Dis Treat 2007;3(6):799-809
   PubMedGoogle Scholar
• Gras J, Bou J, Llenas J, Functional profile of almotriptan in animal models predictive of antimigraine activity. Eur J Pharmacol 2000;410:43-51
   PubMed Web of Science ®Google Scholar
• Bou J, Gras J, Cortijo J, Vascular effects of the new antimigraine agent almotriptan on human cranial and peripheral arteries. Cephalalgia 2001;21:804-12
   PubMed Web of Science ®Google Scholar
• Jansat JM, Costa J, Salsa P, Absolute bioavailability, pharmacokinetics, and urinary excretion of the novel antimigraine agent almotriptan in healty male volunteers. J Clin Pharmacol 2002;42:1303-10
   PubMed Web of Science ®Google Scholar
• Gras J, Lleans J, Jansat JM, Almotriptan, a new antimigraine agent: a review. CNS Drug Rev 2002;8:217-34
   PubMedGoogle Scholar
• Ferrari A, Tiraferri I, Neri L, Why pharmacokinetic differences among oral triptans have little clinical importance: a comment. J Headache Pain 2011;12(1):5-12
   PubMed Web of Science ®Google Scholar
• Baldwin JR, Fleishaker JC, Azie NE, A comparison of the pharmacokinetics and tolerability of the anti-migraine compound almotriptan in healthy adolescents and adults. Cephalalgia 2004;24:288-92
   PubMed Web of Science ®Google Scholar
• Salva M, Jansat JM, Martinez-Tobed A, Identification of the human liver enzymes involved in the metabolism of the antimigraine agent almotriptan. Drug Metab Dispos 2003;31:404-11
   PubMed Web of Science ®Google Scholar
• Dodick DW. A review of the clinical efficacy and tolerability of almotriptan in acute migraine. Expert Opin Pharmacother 2003;4:1157-63
   PubMed Web of Science ®Google Scholar
• Jansat JM, Martinez-Tobed A, Garcia E, Effect of food intake on the bioavailability of almotriptan, an antimigraine compound, in healthy volunteers: an open, randomized, crossover, single-dose clinical trial. Int J Clin Pharmacol Ther 2006;44:185-90
   PubMed Web of Science ®Google Scholar
• Cabarrocas X, Salva M, Pavesi M, Ethanol does not significantly affect the bioavailability of almotriptan: an open, randomized, crossover, single-dose, phase I clinical trial in healthy volunteers. Int J Clin Pharmacol Ther 2006;44:443-8
   PubMed Web of Science ®Google Scholar
• Fleishaker JC, Ryan KK, Carel BJ, Evaluation of the potential pharmacokinetic interaction between almotriptan and fluoxetine in healthy volunteers. J Clin Pharmacol 2001;41:217-23
   PubMed Web of Science ®Google Scholar
• Fleishaker JC, Ryan KK, Jansat JM, Effect of MAO-A inhibition on the pharmacokinetics of almotriptan, an antimigraine agent in humans. Br J Clin Pharmacol 2001;51:437-41
   PubMed Web of Science ®Google Scholar
• Fleishaker JC, Sisson TA, Carel BJ, Lack of pharmacokinetic interaction between the antimigraine compound, almotriptan, and propranolol in healthy volunteers. Cephalalgia 2001;21:61-5
   PubMed Web of Science ®Google Scholar
• Fleishaker JC, Sisson TA, Carel BJ, Pharmacokinetic interaction between verapamil and almotriptan in healthy volunteers. Clin Pharmacol Ther 2000;67:498-503
   PubMed Web of Science ®Google Scholar
• Fleishaker JC, Herman BD, Carel BJ, Interaction between ketoconazole and almotriptan in healthy volunteers. J Clin Pharmacol 2003;43:423-7
   PubMed Web of Science ®Google Scholar
• Sclar DA, Robison LM, Castillo LV, Concomitant use of triptan, and SSRI or SNRI after the US Food and Drug Administration alert on serotonin syndrome. Headache 2012;52(2):198-203
   PubMed Web of Science ®Google Scholar
• Dahlöf C, Tfelt-Hansen P, Massiou H, Almotriptan Study Group. Dose finding, placebo-controlled study of oral almotriptan in the acute treatment of migraine. Neurology 2001;57:1811-17
   PubMed Web of Science ®Google Scholar
• Dahlöf CG, Pascual J, Dodick DW, Dowson AJ. Efficacy, speed of action and tolerability of almotriptan in the acute treatment of migraine: pooled individual patient data from four randomized, double-blind, placebo-controlled clinical trials. Cephalalgia 2006;26(4):400-8
   PubMed Web of Science ®Google Scholar
• Pascual J, Falk RM, Piessens F, Consistent efficacy and tolerability of almotriptan in the acute treatment of multiple migraine attacks: results of a large, randomized, double-blind, placebo-controlled study. Cephalalgia 2000;20:588-96
   PubMed Web of Science ®Google Scholar
• Pascual J, Falk R, Docekal R, Tolerability and efficacy of almotriptan in the long-term treatment of migraine. Eur Neurol 2001;45:206-13
   PubMed Web of Science ®Google Scholar
• Cabarrocas X, Esbri R, Peris F, Long-term efficacy and safety of oral almotriptan: interim analysis of a 1-year open study. Headache 2001;41:57-62
   PubMed Web of Science ®Google Scholar
• Linder SL, Mathew NT, Cady RK, Efficacy and tolerability of almotriptan in adolescents: a randomized, double-blind, placebo-controlled trial. Headache 2008;48:1326-36
   PubMed Web of Science ®Google Scholar
• Berenson F, Vasconcellos E, Pakalnis A, Long-term, open-label safety study of oral almotriptan 12.5 mg for the acute treatment of migraine in adolescents. Headache 2010;50:795-807
   PubMed Web of Science ®Google Scholar
• Diamond ML, Cady RK, Mao L, Characteristics of migraine attacks and responses to almotriptan treatment: a comparison of menstrually related and nonmenstrually related migraines. Headache 2008;48:248-58
   PubMed Web of Science ®Google Scholar
• Allais G, Acuto G, Cabarrocas X, Efficacy and tolerability of almotriptan versus zolmitriptan for the acute treatment of menstrual migraine. Neurol Sci 2006;27(Suppl 2):S193-7
   PubMed Web of Science ®Google Scholar
• Allais G, Bussone G, D'Andrea G, Almotriptan 12.5 mg in menstrually related migraine: a randomized, double-blind, placebo-controlled study. Cephalalgia 2011;31:144-51
   PubMed Web of Science ®Google Scholar
• Bartolini M, Giamberardino MA, Lisotto C, Frovatriptan versus almotriptan for acute treatment of menstrual migraine: analysis of a double-blind, randomized, cross-over, multicenter, Italian, comparative study. J Headache Pain 2012;13:401-6
   PubMed Web of Science ®Google Scholar
• Allais G, Acuto G, Benedetto C, Evolution of migraine-associated symptoms in menstrually related migraine following symptomatic treatment with almotriptan. Neurol Sci 2010;31(Suppl 1):S115-19
   PubMedGoogle Scholar
• Bussone G, Allais G, Castagnoli Gabellari I, Almotriptan for menstrually related migraine. Expert Opin Pharmacother 2011;12:1933-43
   PubMed Web of Science ®Google Scholar
• Lionetto L, Fiorillo M, Martelletti P. Efficacy and tolerability of almotriptan in menstrual migraine: a comment. Expert Opin Pharmacother 2011;12:2279-81
   PubMed Web of Science ®Google Scholar
• Pascual J, Diener HC. Use of almotriptan in triptan-experienced and triptan-naïve patients. Curr Med Res Opin 2007;23:2433-40
   PubMed Web of Science ®Google Scholar
• Bermejo PE, Dorado R, Gomez-Arguelles JM. Variation in almotriptan effectiveness according to different prophylactic treatments. Headache 2009;49:1277-82
   PubMed Web of Science ®Google Scholar
• Mathew NT. Early intervention with almotriptan improves sustained pain-free response in acute migraine. Headache 2003;43:1075-9
   PubMed Web of Science ®Google Scholar
• Goadsby PJ, Zanchin G, Geraud G, Early vs. non-early intervention in acute migraine-‘Act when Mild (AwM)'. A double-blind, placebo-controlled trial of almotriptan. Cephalalgia 2008;28:383-91
   PubMed Web of Science ®Google Scholar
• Pascual J, Cabarrocas X. Within-patient early versus delayed treatment of migraine attacks with almotriptan: the sooner the better. Headache 2002;42:28-31
   PubMed Web of Science ®Google Scholar
• Dowson AJ, Massiou H, Lainez JM, Almotriptan improves response rates when treatment is within 1 hour of migraine onset. Headache 2004;44:318-22
   PubMed Web of Science ®Google Scholar
• Freitag FG, Finlayson G, Rapoport AM, AIMS Investigators. Effect of pain intensity and time to administration on responsiveness to almotriptan: results from AXERT 12.5 mg Time Versus Intensity Migraine Study (AIMS). Headache 2007;47:519-30
   PubMed Web of Science ®Google Scholar
• Mathew NT, Finlayson G, Smith TR, AEGIS Investigator Study Group. Early intervention with almotriptan: results of the AEGIS trial (AXERT Early Migraine Intervention Study). Headache 2007;47:189-98
   PubMed Web of Science ®Google Scholar
• Díaz-Insa S, Goadsby PJ, Zanchin G, The impact of allodynia on the efficacy of almotriptan when given early in migraine: data from the "Act when mild" study. Int J Neurosci 2011;121:655-61
   PubMed Web of Science ®Google Scholar
• Freitag F, Smith T, Mathew N, AEGIS Investigator Study Group. Effect of early intervention with almotriptan vs placebo on migraine-associated functional disability: results from the AEGIS Trial. Headache 2008;48:341-54
   PubMed Web of Science ®Google Scholar
• Lanteri-Minet M, Díaz-Insa S, Leone M, START Study. Efficacy of almotriptan in early intervention for treatment of acute migraine in a primary care setting: the START study. Int J Clin Pract 2010;64:936-43
   PubMed Web of Science ®Google Scholar
• Leone M, Vila C, McGown C. Influence of trigger factors on the efficacy of almotriptan as early intervention for the treatment of acute migraine in a primary care setting: the START study. Expert Rev Neurother 2010;10:1399-408
   PubMed Web of Science ®Google Scholar
• Spierings EL, Gomez-Mancilla B, Grosz DE, Oral almotriptan vs. oral sumatriptan in the abortive treatment of migraine: a double-blind, randomized, parallel-group, optimum-dose comparison. Arch Neurol 2001;58:944-50
   PubMed Web of Science ®Google Scholar
• Dowson AJ, Massiou H, Laínez JM, Almotriptan is an effective and well-tolerated treatment for migraine pain: results of a randomized, double-blind, placebo-controlled clinical trial. Cephalalgia 2002;22:453-61
   PubMed Web of Science ®Google Scholar
• Cady R. Almotriptan reduces the incidence of migraine-associated symptoms: a pooled analysis. Headache 2002;42(Suppl 1):26-31
   PubMedGoogle Scholar
• Ferrari MD, Goadsby PJ, Roon KI, Triptans (serotonin, 5-HT1B/1D agonists) in migraine: detailed results and methods of a meta-analysis of 53 trials. Cephalalgia 2002;22:633-58
   PubMed Web of Science ®Google Scholar
• Dodick DW, Sandrini G, Williams P. Use of the sustained pain-free plus no adverse events endpoint in clinical trials of triptans in acute migraine. CNS Drugs 2007;21:73-82
   PubMed Web of Science ®Google Scholar
• Goadsby PJ, Massiou H, Pascual J, Almotriptan and zolmitriptan in the acute treatment of migraine. Acta Neurol Scand 2007;115:34-40
   PubMed Web of Science ®Google Scholar
• Bartolini M, Giamberardino MA, Lisotto C, A double-blind, randomized, multicenter, Italian study of frovatriptan versus almotriptan for the acute treatment of migraine. J Headache Pain 2011;12:361-8
   PubMed Web of Science ®Google Scholar
• Chen LC, Ashcroft DM. Meta-analysis examining the efficacy and safety of almotriptan in the acute treatment of migraine. Headache 2007;47:1169-77
   PubMed Web of Science ®Google Scholar
• Dodick DW. Oral almotriptan in the treatment of migraine: safety and tolerability. Headache 2001;41:449-55
   PubMed Web of Science ®Google Scholar
• Dodick DW, Martin V. Triptans and CNS side-effects: pharmacokinetic and metabolic mechanisms. Cephalalgia 2004;24:417-24
   PubMed Web of Science ®Google Scholar
• Lewis DW. Almotriptan for the acute treatment of adolescent migraine. Expert Opin Pharmacother 2010;11:2431-6
   PubMed Web of Science ®Google Scholar
• Colman SS, Brod MI, Krishnamurthy A, Treatment satisfaction, functional status, and health-related quality of life of migraine patients treated with almotriptan or sumatriptan. Clin Ther 2001;23:127-45
   PubMed Web of Science ®Google Scholar
• Diener HC. Consistent efficacy, tolerability, and high levels of satisfaction with almotriptan 12.5 mg when used to treat multiple migraine attacks in routine clinical practice. Headache 2005;45:624-31
   PubMed Web of Science ®Google Scholar
• Díaz-Insa S, Vila C, McGown CC. Improved patient satisfaction and pain evolution with almotriptan in migraine: a primary care study. Curr Med Res Opin 2011;27:559-67
   PubMed Web of Science ®Google Scholar
• Wang JT, Barr CE, Goldfarb SD. Impact of chest pain on cost of migraine treatment with almotriptan and sumatriptan. Headache 2002;42(Suppl 1):38-43
   PubMedGoogle Scholar
• Geraud G, Keywood C, Senard JM. Migraine headache recurrence: relationship to clinical, pharmacological, and pharmacokinetic properties of triptans. Headache 2003;43:376-88
   PubMed Web of Science ®Google Scholar
• Sarchielli P, Granella F, Prudenzano MP, Italian guidelines for primary headaches: 2012 revised version. J Headache Pain 2012;13(Suppl 2):31-70
   PubMed Web of Science ®Google Scholar
• Corbelli I, Caproni S, Eusebi P, Drug-dependence behaviour and outcome of medication-overuse headache after treatment. J Headache Pain 2012;13(8):653-60
   PubMed Web of Science ®Google Scholar
• De Felice M, Ossipov MH, Wang R, Triptan-induced enhancement of neuronal nitric oxide synthase in trigeminal ganglion dural afferents underlies increased responsiveness to potential migraine triggers. Brain 2010;133(Pt 8):2475-88
   PubMedGoogle Scholar
• Dodick D, Lipton RB, Martin V, Consensus statement: cardiovascular safety profile of triptans (5-HT1B/1D agonists) in the acute treatment of migraine. Headache 2004;44:414-25
   PubMed Web of Science ®Google Scholar
• Negro A, Lionetto L, Simmaco M, Martelletti P. CGRP receptor antagonists: an expanding drug class for acute migraine? Expert Opin Investig Drugs 2012;21:807-18
   PubMed Web of Science ®Google Scholar
• Lionetto L, Negro A, Palmisani S, Emerging treatment for chronic migraine and refractory chronic migraine. Expert Opin Emerg Drugs 2012;17(3):393-406
   PubMed Web of Science ®Google Scholar
• Saxena PR, Tfelt-Hansen P. Triptans, 5HT1B/1D agonists in the acute treatment of migraine In: Olesen J, Goadsby PJ, Ramadan NM, Tfelt-Hansen P, Welch KMA, editors. The headaches. 3rd edition, 2006. pp. 469-503
   Google Scholar
• Saxena PR, Tfelt-Hansen P. Success and failure of triptans. J Headaches 2001;2:3-11
   Google Scholar